INO
Price
$13.88
Change
+$0.85 (+6.52%)
Updated
Mar 28, 6:59 PM EST
41 days until earnings call
NVAX
Price
$4.78
Change
-$0.07 (-1.44%)
Updated
Mar 28, 6:59 PM EST
40 days until earnings call
Ad is loading...

Analysis and predictions INO vs NVAX

Header iconINO vs NVAX Comparison
Open Charts INO vs NVAXBanner chart's image
Inovio Pharmaceuticals
Price$13.88
Change+$0.85 (+6.52%)
Volume$512.27K
CapitalizationN/A
Novavax
Price$4.78
Change-$0.07 (-1.44%)
Volume$2.36M
CapitalizationN/A
View a ticker or compare two or three
INO vs NVAX Comparison Chart

Loading...

INODaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
INO vs. NVAX commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a StrongBuy and NVAX is a Hold.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (INO: $13.85 vs. NVAX: $4.76)
Brand notoriety: INO and NVAX are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 142% vs. NVAX: 38%
Market capitalization -- INO: $323.68M vs. NVAX: $666.88M
INO [@Biotechnology] is valued at $323.68M. NVAX’s [@Biotechnology] market capitalization is $666.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • INO’s TA Score: 3 bullish, 4 bearish.
  • NVAX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than INO.

Price Growth

INO (@Biotechnology) experienced а +26.14% price change this week, while NVAX (@Biotechnology) price change was +0.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

INO is expected to report earnings on May 08, 2024.

NVAX is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVAX($667M) has a higher market cap than INO($324M). INO YTD gains are higher at: 126.797 vs. NVAX (-0.729). INO has higher annual earnings (EBITDA): -130.39M vs. NVAX (-487.39M). NVAX has more cash in the bank: 569M vs. INO (145M). INO has less debt than NVAX: INO (30.2M) vs NVAX (229M). NVAX has higher revenues than INO: NVAX (556M) vs INO (832K).
INONVAXINO / NVAX
Capitalization324M667M49%
EBITDA-130.39M-487.39M27%
Gain YTD126.797-0.729-17,389%
P/E RatioN/AN/A-
Revenue832K556M0%
Total Cash145M569M25%
Total Debt30.2M229M13%
FUNDAMENTALS RATINGS
INO vs NVAX: Fundamental Ratings
INO
NVAX
OUTLOOK RATING
1..100
9068
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5078
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (71) in the Medical Specialties industry is in the same range as NVAX (86) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's Price Growth Rating (50) in the Medical Specialties industry is in the same range as NVAX (78) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INONVAX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 23 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
INODaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHXYX14.660.08
+0.55%
American Beacon Shapiro Equity Opps Y
FASMX20.360.01
+0.05%
Fidelity Asset Manager 50%
RSCKX5.19N/A
N/A
Victory RS Small Cap Equity R
PCEKX22.46N/A
N/A
Pioneer Core Equity K
BGLUX32.63-0.08
-0.24%
Baron Global Advantage R6